Instructions: Print this exam worksheet. Return to the course page using the link below. Read the course material. Enter your answers on this worksheet. Return to the course page and click the link 'Take Test.' Transfer your answers.

https://www.quantumunitsed.com/go/736

Quantum Units Education®

Opioid Use Disorder: Medications, Screening, and Assessment

Part 1: Introduction to Medications for Opioid Use Disorder Treatment

1. Opioid addiction, which generally corresponds with moderate to severe forms of OUD, often requires continuing care for effective treatment rather than an episodic, acute-care treatment approach.

A. True

B. False


2. Which of the following does not count toward the diagnosis of OUD when using opioids under appropriate medical supervision?

A. Tolerance

B. Withdrawal

C. Both (A) and (B)

D. None of the above


3. The TIP expert panel recommends that providers always use:

A. Medical terms when discussing SUDs.

B. Person-first language.

C. Both (A) and (B).

D. None of the above.


4. Naltrexone does all of the following, except:

A. Reduce or eliminate withdrawal symptoms.

B. Blunt or block the effects of illicit opioids.

C. Reduce or eliminate cravings to use opioids.

D. Naltrexone does all of the above.


5. Which of the following is not a scheduled medication?

A. Methadone

B. Naltrexone

C. Buprenorphine

D. All of the above are scheduled medications


6. Patients receiving treatment in which setting should have access to FDA-approved medications for OUD?

A. Outpatient counseling

B. Inpatient treatment

C. Long-term therapeutic communities

D. All of the above


7. In a study comparing XR-NTX to sublingual buprenorphine, when comparing only those who started their assigned medication, patients taking buprenorphine had significantly lower relapse rates during 24 weeks of outpatient treatment than patients assigned to XR-NTX.

A. True

B. False


8. All of the following are exceptions in the Controlled Substances Act from the requirement to provide methadone through an OTP or buprenorphine through an OTP or a waivered practitioner, except for:

A. Administering an opioid for no more than 3 days to a patient in acute opioid withdrawal while preparations are made for ongoing care.

B. Prescribing an opioid for no more than 3 days to a patient in acute opioid withdrawal while preparations are made for ongoing care.

C. Administering opioid medications in a hospital to maintain or detoxify a patient as an “incidental adjunct to medical or surgical treatment of conditions other than addiction.”

D. All of the above are exceptions from the requirement to provide methadone through an OTP or buprenorphine through an OTP or a waivered practitioner.


9. Patients who discontinue OUD medication generally return to illicit opioid use.

A. True

B. False


10. Providers and their patients should base decisions about discontinuing OUD medication on all of the following, except:

A. Arbitrary time limits on the duration of treatment with OUD mediation.

B. Knowledge of the evidence base for the use of OUD medication.

C. Individualized assessments.

D. An individualized treatment plan both collaboratively develop and agree upon.


11. Adding psychosocial treatments to taper regimens always significantly improves outcomes compared with remaining on medication.

A. True

B. False


12. Psychosocial treatment strategies, such as contingency management, can reduce:

A. Dropout from medically supervised withdrawal.

B. Opioid use during withdrawal.

C. Opioid use following completion of withdrawal.

D. All of the above.


13. Medically supervised withdrawal is necessary for patients starting _____, which requires at least 7 days without short-acting opioids and 10 to 14 days without long-acting opioids.

A. Methadone

B. Naltrexone

C. Buprenorphine

D. All of the above


14. Patients who complete medically supervised withdrawal are at risk of opioid overdose.

A. True

B. False


Part 2: Addressing Opioid Use Disorder in General Medical Settings

15. The TIP expert panel recommends that healthcare professionals screen patients for _____ use at least annually.

A. Alcohol and tobacco

B. Prescription drug

C. Illicit drug

D. All of the above


16. Providers should warn patients who use opioids that _____ may increase opioid overdose risk.

A. Alcohol

B. Tobacco

C. Prescription drugs

D. All of the above


17. USPSTF’s position is to recommend for routine screening for illicit drug use in primary care.

A. True

B. False


18. Patients should be assessed for an OUD if:

A. They screen positive for opioid misuse.

B. They disclose opioid misuse.

C. Signs and symptoms of opioid misuse are present.

D. All of the above.


19. If a provider does not offer pharmacotherapy, the focus should be on:

A. Medical assessment

B. Making a diagnosis of OUD

C. Patient safety

D. All of the above


20. Which of the following questions may come across as judgmental to the patient who already feels ashamed and defensive?

A. In what ways has oxycodone affected your life?

B. What could you do to prevent infections like this in the future?

C. Has oxycodone caused your family trouble?

D. All of the above come across as judgmental.


21. Treatment for mental disorders and SUDs can occur concurrently.

A. True

B. False


22. Which of the following can cause complications for patients who misuse or have SUDs involving alcohol or benzodiazepines?

A. Buprenorphine

B. Methadone

C. Both (A) and (B)

D. None of the above


23. Patients coerced into treatment are less likely to succeed in treatment compared to patients engaging voluntarily.

A. True

B. False


24. One of the strongest risk factors for developing SUDs is:

A. Being exposed to substance use in the household during childhood.

B. Having a parent with an SUD.

C. Having a sibling with an SUD.

D. Having a partner with an SUD.


25. Snorting opioids can cause:

A. Congestion and damage nasal mucosa.

B. Heart murmur secondary to endocarditis.

C. Jaundice or an enlarged or hardened liver secondary to liver disease.

D. All of the above.


26. During ongoing pharmacotherapy with buprenorphine or methadone, drug testing can confirm medication adherence.

A. True

B. False


27. The typical opioid immunoassay will detect:

A. Morphine

B. Methadone

C. Buprenorphine

D. Fentanyl


28. Typical benzodiazepine urine immunoassays will detect:

A. Lorazepam

B. Clonazepam

C. Diazepam

D. All of the above


29. It is not advisable for patients to start _____ during pregnancy.

A. Methadone

B. Naltrexone

C. Buprenorphine

D. All of the above


30. Every patient who misuses opioids or has OUD should receive:

A. Opioid overdose prevention education.

B. A naloxone prescription.

C. Both (A) and (B).

D. None of the above.


Copyright © 2020 Quantum Units Education

Visit us at QuantumUnitsEd.com!